On December 3, 2014, the first subject was enrolled in our Canadian study of MDMA-assisted psychotherapy for PTSD, led by Principal Investigator Ingrid Pacey, M.D., in Vancouver, BC. Goals for this study include (1) gathering evidence about the safety and effectiveness of MDMA-assisted psychotherapy in subjects with chronic, treatment-resistant PTSD from a skilled co-therapist team, (2) gathering information about the range of outcomes from different co-therapist teams for the design of our Phase 3 studies, and (3) initiating the first Canadian research into the potential benefits of psychedelic psychotherapy in over 40 years. “We began this journey in 2009, when we approached Health Canada about doing a Canadian MDMA/PTSD study,” recalls Dr. Pacey. “Our team has grown since then, with our new co-therapists Donna Dryer, M.D., and Richard Yensen, Ph.D., and our steady study coordinator Deborah Kraus. We are excited and amazed that we have finally enrolled our first subject. It has taken all of us plus many others to get here.” Learn more…